SAB BIOTHERAPEUTICS INC reports a Return on Equity (ROE) of -0.18%.

What is SABSW's dividend yield?

SAB BIOTHERAPEUTICS INC offers a dividend yield of 0.00%.

What is SABSW's Deepscope Quality Score?

Deepscope rates SABSW's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy SABSW?

Deepscope's AI Timing Score for SABSW is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

SABSW (NASDAQ) 株価分析 | SAB BIOTHERAPEUTICS INC

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-12 | FS: 2026-03-31)

SABSW

SAB BIOTHERAPEUTICS INC

US:NASDAQ STOCK News 89

USD 0.01

-0.02 (-64.80%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

-0.2%

ROE

-0.2%

ROA

0.00%

Div Yield

SAB BIOTHERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.01 Price -0.02 (-64.80%) Day Change	NEWS SCORE: 89

SABSW, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Deepscope 分析

38%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	89
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.01
PBV / Sector	N/A / N/A
Earning Per Share	N/A

PE / Sector	N/A / N/A
PEG or PE/Growth / Sector	N/A / N/A
Average 1M Daily Value	437.555700000000
Average 1W Daily Value	67.382520000000 GOOD

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

43%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / N/A
NPM Average (%) / Sector	-1,513.98 / N/A
NPM Change Average (%) / Sector	N/A / N/A
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-0.16 / N/A
ROA Average (%) / Sector	-31.35 / N/A
ROA Change Average (%) / Sector	-30.50 / N/A
ROE (%) / Sector	-0.18 / N/A
ROE Average (%) / Sector	-51.34 / N/A
ROE Change Average (%) / Sector	-27.07 / N/A
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / N/A
Dividend Average (%) / Sector	N/A / N/A
Dividend Change Average (%) / Sector	N/A / N/A

登録情報

Analyze Date	2026-06-13 11:13:54
Symbol	SABSW
Name	SAB BIOTHERAPEUTICS INC
Sector
Market	NASDAQ
Listed Shares	0.00
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	N/A / N/A

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 777 W 41st St., Miami Beach, FL, United States, 33140

Phone: 305 845 2813

Website: https://www.sab.bio

Employees: 86

Sector: -

Description: SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.